Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology

Area of Science:

• Oncology
• Urology

Background:

• Prostate cancer management requires tailored strategies across different disease stages.
• Current guidelines address metastatic castration-sensitive prostate cancer (mCSPC) and castration-resistant prostate cancer (CRPC).

Purpose of the Study:

• To outline the NCCN Guidelines for prostate cancer treatment decision-making.
• To detail therapeutic approaches for mCSPC and CRPC based on disease characteristics.

Main Methods:

• Review of NCCN Guidelines for prostate cancer.
• Focus on treatment considerations for mCSPC and CRPC stages.
• Emphasis on shared decision-making principles.

Main Results:

• Treatment decisions for mCSPC depend on metastasis timing and burden, influencing therapy intensification and directed therapies.
• mCRPC management involves continuing androgen deprivation therapy with added agents like AR pathway inhibitors, chemotherapy, immunotherapy, radiopharmaceuticals, or targeted therapies.
• NCCN panel highlights shared decision-making based on patient preferences, history, biomarkers, metastasis extent, symptoms, and side effects.

Conclusions:

• The NCCN Guidelines provide a comprehensive framework for prostate cancer management.
• Personalized treatment strategies are crucial for both mCSPC and CRPC.
• Shared decision-making is integral to optimizing patient outcomes in prostate cancer care.